SynthesisWorld journal of surgical oncology2025
Prognostic role of the baseline neutrophil‒eosinophil ratio in cancer patients: a meta-analysis and systematic review.
Synthesis in World journal of surgical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Study on risk stratification and treatment strategy of blood indicators in patients with moderate risk of GIST.Frontiers in oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundInflammation impacts the prognosis of numerous types of tumors. Inflammatory indicators such as the neutrophil-to-lymphocyte ratio, lymphocyte-to-monocyte ratio, and neutrophil-to-eosinophil ratio (NER) have emerged as potential prognostic markers and are closely correlated with the outcomes of cancer patients. However, the connection between NER and cancer prognosis remains incompletely understood. Therefore, we conducted a meta-analysis to investigate the potential of the inflammatory marker NER as a prognostic indicator in cancer patients.
methodsA thorough search was conducted across PubMed, Embase, Web of Science, and the Cochrane Library, with a cutoff date of August 2024. Relevant data were extracted, and hazard ratios (HRs) and relative risks (RRs), along with their corresponding 95% confidence intervals (CIs), were calculated to assess the prognostic impact of the NER on overall survival (OS), progression-free survival (PFS), and the objective response rate (ORR). Stata version 18 statistical software was utilized for the meta-analysis of the literature that met the inclusion criteria.
resultsSeven cohort studies encompassing a total of 1,336 cancer patients were included in this meta-analysis. These findings indicate that lower NER is associated with improved PFS in cancer patients. Additionally, in cancer patients undergoing immunotherapy, lower NER levels are linked to a better ORR. A lower NER is correlated with improved OS and ORR in patients with metastatic renal cancer who are receiving immunotherapy.
conclusionIn cancer patients, elevated NER is associated with poorer PFS and ORR. Similarly, high NER levels in patients with metastatic renal cell carcinoma undergoing immunotherapy are linked to worse OS and ORR. The inflammatory marker NER, which serves as an efficacious prognostic indicator for cancer patients, offers profound insights into related cancers in the context of immunotherapy. In the future, high-quality prospective studies are warranted to corroborate these findings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.